Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more
-
- Masahiko Shibata
- Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan
-
- Kotaro Nanno
- Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan
-
- Daigo Yoshimori
- Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan
-
- Takahiro Nakajima
- Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan
-
- Makoto Takada
- Aizu Oncology Consortium, Fukushima, Japan
-
- Takashi Yazawa
- Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan
-
- Kousaku Mimura
- Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan
-
- Norio Inoue
- Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan
-
- Takafumi Watanabe
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
-
- Kazunoshin Tachibana
- Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan
-
- Satoshi Muto
- Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan
-
- Tomoyuki Momma
- Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan
-
- Yoshiyuki Suzuki
- Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan
-
- Koji Kono
- Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan
-
- Shungo Endo
- Department of Colorectoanal Surgery, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan
-
- Seiichi Takenoshita
- Fukushima Medical University, Fukushima, Japan
説明
Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review. Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.
収録刊行物
-
- Oncotarget
-
Oncotarget 13 (1), 1273-1285, 2022-11-17
Impact Journals, LLC